Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All favipiravir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchFavipiravirFavipiravir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

The Effectiveness and Safety of Favipiravir in COVID-19 Hospitalized Patients in Bali, Indonesia

Damayanti et al., Kesmas: National Public Health Journal, doi:10.21109/kesmas.v16i4.5433
Nov 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
0 0.5 1 1.5 2+ Recovery 54% Improvement Relative Risk Favipiravir  Damayanti et al.  LATE TREATMENT Is late treatment with favipiravir beneficial for COVID-19? Retrospective 192 patients in Indonesia Improved recovery with favipiravir (p=0.029) c19early.org Damayanti et al., Kesmas: National Pub.., Nov 2021 Favors favipiravir Favors control
Retrospective 192 hospitalized patients in Indonesia, 96 patients treated with favipiravir, showing improved recovery with treatment. Only the abstract is currently available.
This study is excluded in the after exclusion results of meta analysis: minimal details provided.
risk of no recovery, 54.5% lower, RR 0.46, p = 0.03, treatment 96, control 96, adjusted per study, inverted to make RR<1 favor treatment.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Damayanti et al., 1 Nov 2021, retrospective, Indonesia, peer-reviewed, 4 authors.
This PaperFavipiravirAll
{ 'indexed': {'date-parts': [[2022, 3, 30]], 'date-time': '2022-03-30T12:47:26Z', 'timestamp': 1648644446076}, 'reference-count': 0, 'publisher': 'Kesmas: Jurnal Kesehatan Masyarakat Nasional', 'issue': '4', 'license': [ { 'start': { 'date-parts': [[2021, 11, 1]], 'date-time': '2021-11-01T00:00:00Z', 'timestamp': 1635724800000}, 'content-version': 'unspecified', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by-sa/4.0'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'abstract': '<jats:p>COVID-19 is a major public health problem, with still questionable specific cure. ' 'Favipiravir is a COVID-19 antiviral that is potentially a therapy for COVID-19. This study ' 'aimed to analyze its effectivity and safety in moderate to critical hospitalized patients. ' 'This study was a retrospective cohort in a tertiary referral hospital in Denpasar City, Bali ' 'Province, Indonesia, from August 2020 to January 2021. There was a total of 192 patients; 96 ' 'in the favipiravir group and 96in the non-favipiravir group (remdesivir/oseltamivir). ' 'Effectivity was measured by assessing the clinical condition at the end of the isolation ' 'period of 14 days. The favipiravir group showed better clinical conditions than the ' 'non-favipiravir group (79.2% vs. 56.3%; adjusted RR = 2.196; 95% CI = 1.084 – 4.451; p-value= ' '0.029), seen from being free of fever and respiratory problems. Stratification analysis ' 'demonstrated that the clinical improvement was significantly differentin the severe/critical ' 'group in favor of favipiravir (RR = 1.573; 95% CI = 1.139-2.172). The most common non-serious ' 'adverse events (AE) found in the use offavipiravir were gastrointestinal disturbances ' '(12.5%). In brief, favipiravir is effective in severe/critical cases, and less serious AE ' 'were found in its use. Appropriate treatment is expected to help in reducing the public ' 'health burden.</jats:p>', 'DOI': '10.21109/kesmas.v16i4.5433', 'type': 'journal-article', 'created': {'date-parts': [[2021, 11, 3]], 'date-time': '2021-11-03T01:05:07Z', 'timestamp': 1635901507000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'The Effectiveness and Safety of Favipiravir in COVID-19 Hospitalized Patients at Tertiary ' 'Referral Hospital, Bali, Indonesia', 'prefix': '10.21109', 'volume': '16', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-2437-5072', 'authenticated-orcid': False, 'given': 'Herni', 'family': 'Damayanti', 'sequence': 'first', 'affiliation': []}, {'given': 'I Gede K', 'family': 'Sajinadiyasa', 'sequence': 'additional', 'affiliation': []}, {'given': 'Hindun Wilda', 'family': 'Risni', 'sequence': 'additional', 'affiliation': []}, {'given': 'Rani', 'family': 'Sauriasari', 'sequence': 'additional', 'affiliation': []}], 'member': '8818', 'published-online': {'date-parts': [[2021, 11, 1]]}, 'container-title': 'Kesmas: National Public Health Journal', 'original-title': [], 'link': [ { 'URL': 'https://journal.fkm.ui.ac.id/kesmas/article/viewFile/5433/1245', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://journal.fkm.ui.ac.id/kesmas/article/viewFile/5433/1245', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 12, 6]], 'date-time': '2021-12-06T13:17:05Z', 'timestamp': 1638796625000}, 'score': 1, 'resource': {'primary': {'URL': 'https://journal.fkm.ui.ac.id/kesmas/article/view/5433'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 11, 1]]}, 'references-count': 0, 'journal-issue': {'issue': '4', 'published-online': {'date-parts': [[2021, 11, 1]]}}, 'URL': 'http://dx.doi.org/10.21109/kesmas.v16i4.5433', 'relation': {}, 'ISSN': ['2460-0601', '1907-7505'], 'subject': ['Public Health, Environmental and Occupational Health', 'Health Policy', 'Epidemiology'], 'container-title-short': 'Kesmas: National Public Health Journal', 'published': {'date-parts': [[2021, 11, 1]]}}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit